BACKGROUND: Several studies have reported on an association between hepatitis C virus (HCV) antibody status and the development of chronic kidney disease (CKD), but the role of HCV viremia and genotype are not well defined. METHODS: Patients with at least three serum creatinine measurements after 1 January 2004 and known HCV antibody status were included. Baseline was defined as the first eligible estimated glomerular filtration rate (eGFR) (Cockcroft-Gault equation), and CKD was either a confirmed (>3 months apart) eGFR of 60 ml/min per 1.73 m or less for patients with a baseline eGFR more than 60 ml/min per 1.73 m or a confirmed 25% decline in eGFR for patients with a baseline eGFR of 60 ml/min per 1.73 m or less. Incidence rates of CKD were compared between HCV groups (anti-HCV-negative, anti-HCV-positive with or without viremia) using Poisson regression. RESULTS: Of 8235 patients with known anti-HCV status, 2052 (24.9%) were anti-HCV-positive of whom 983 (47.9%) were HCV-RNA-positive, 193 (9.4%) HCV-RNA-negative and 876 (42.7%) had unknown HCV-RNA. At baseline, the median eGFR was 97.6 (interquartile range 83.8-113.0) ml/min per 1.73 m. During 36123 person-years of follow-up (PYFU), 495 patients progressed to CKD (6.0%) with an incidence rate of 14.5 per 1000 PYFU (95% confidence interval 12.5-14.9). In a multivariate Poisson model, patients who were anti-HCV-positive with HCV viremia had a higher incidence rate of CKD, whereas patients with cleared HCV infection had a similar incidence rate of CKD compared with anti-HCV-negative patients. There was no association between CKD and HCV genotype. CONCLUSION: Compared with HIV-monoinfected patients, HIV-positive patients with chronic rather than cleared HCV infection were at increased risk of developing CKD, suggesting a contribution from active HCV infection toward the pathogenesis of CKD.
BACKGROUND: Several studies have reported on an association between hepatitis C virus (HCV) antibody status and the development of chronic kidney disease (CKD), but the role of HCV viremia and genotype are not well defined. METHODS:Patients with at least three serum creatinine measurements after 1 January 2004 and known HCV antibody status were included. Baseline was defined as the first eligible estimated glomerular filtration rate (eGFR) (Cockcroft-Gault equation), and CKD was either a confirmed (>3 months apart) eGFR of 60 ml/min per 1.73 m or less for patients with a baseline eGFR more than 60 ml/min per 1.73 m or a confirmed 25% decline in eGFR for patients with a baseline eGFR of 60 ml/min per 1.73 m or less. Incidence rates of CKD were compared between HCV groups (anti-HCV-negative, anti-HCV-positive with or without viremia) using Poisson regression. RESULTS: Of 8235 patients with known anti-HCV status, 2052 (24.9%) were anti-HCV-positive of whom 983 (47.9%) were HCV-RNA-positive, 193 (9.4%) HCV-RNA-negative and 876 (42.7%) had unknown HCV-RNA. At baseline, the median eGFR was 97.6 (interquartile range 83.8-113.0) ml/min per 1.73 m. During 36123 person-years of follow-up (PYFU), 495 patients progressed to CKD (6.0%) with an incidence rate of 14.5 per 1000 PYFU (95% confidence interval 12.5-14.9). In a multivariate Poisson model, patients who were anti-HCV-positive with HCV viremia had a higher incidence rate of CKD, whereas patients with cleared HCV infection had a similar incidence rate of CKD compared with anti-HCV-negative patients. There was no association between CKD and HCV genotype. CONCLUSION: Compared with HIV-monoinfectedpatients, HIV-positivepatients with chronic rather than cleared HCV infection were at increased risk of developing CKD, suggesting a contribution from active HCV infection toward the pathogenesis of CKD.
Authors: Anda Gonciulea; Ruibin Wang; Keri N Althoff; Michelle M Estrella; Deborah E Sellmeyer; Frank J Palella; Jordan E Lake; Lawrence A Kingsley; Todd T Brown Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: S Leone; M Prosperi; S Costarelli; P Nasta; F Maggiolo; S Di Giambenedetto; A Saracino; M Di Pietro; A Gori Journal: Eur J Clin Microbiol Infect Dis Date: 2016-06-06 Impact factor: 3.267
Authors: Jason Cheung; Rainer Puhr; Kathy Petoumenos; David A Cooper; Ian Woolley; Manoji Gunathilake; Nigel Raymond; Rick Varma; Catherine C O'Connor; David M Gracey Journal: Nephrology (Carlton) Date: 2018-08 Impact factor: 2.506
Authors: G N Nadkarni; A Patel; P K Simoes; R Yacoub; N Annapureddy; S Kamat; I Konstantinidis; P Perumalswami; A Branch; S G Coca; C M Wyatt Journal: J Viral Hepat Date: 2015-07-20 Impact factor: 3.728
Authors: Gregory M Lucas; Yuezhou Jing; Mark Sulkowski; Alison G Abraham; Michelle M Estrella; Mohamed G Atta; Derek M Fine; Marina B Klein; Michael J Silverberg; M John Gill; Richard D Moore; Kelly A Gebo; Timothy R Sterling; Adeel A Butt Journal: J Infect Dis Date: 2013-07-31 Impact factor: 5.226
Authors: Lene Ryom; Amanda Mocroft; Ole Kirk; Signe W Worm; David A Kamara; Peter Reiss; Michael Ross; Christoph A Fux; Philippe Morlat; Olivier Moranne; Colette Smith; Jens D Lundgren Journal: J Infect Dis Date: 2013-02-04 Impact factor: 5.226